-
Mai
Badarni,
M.
Prasad,
N.
Balaban,
Jonathan
Zorea,
Ksenia
Yegodayev,
Joshua
Ben-Zion,
A.
Dinur,
R.
Grénman,
B.
Rotblat,
Limor
Cohen,
M.
Elkabets
(2019)
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
JCI insight, 5
-
(
HarmsPWVatsPVerhaegenME, et al
The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res
2015; 75: 3720–3727.26238782)
HarmsPWVatsPVerhaegenME, et al
The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res
2015; 75: 3720–3727.26238782
HarmsPWVatsPVerhaegenME, et al
The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res
2015; 75: 3720–3727.26238782,
HarmsPWVatsPVerhaegenME, et al
The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res
2015; 75: 3720–3727.26238782
-
(
PotterDSGalvinMBrownS, et al
Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol Cancer Ther
2016; 15: 1248–1260.27197306)
PotterDSGalvinMBrownS, et al
Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol Cancer Ther
2016; 15: 1248–1260.27197306
PotterDSGalvinMBrownS, et al
Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol Cancer Ther
2016; 15: 1248–1260.27197306,
PotterDSGalvinMBrownS, et al
Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol Cancer Ther
2016; 15: 1248–1260.27197306
-
C.
Rudin,
C.
Hann,
E.
Garon,
Moacyr
Oliveira,
P.
Bonomi,
D.
Camidge,
Q.
Chu,
G.
Giaccone,
D.
Khaira,
S.
Ramalingam,
M.
Ranson,
C.
Dive,
E.
Mckeegan,
B.
Chyla,
B.
Dowell,
A.
Chakravartty,
C.
Nolan,
Nikita
Rudersdorf,
T.
Busman,
M.
Mabry,
A.
Krivoshik,
R.
Humerickhouse,
G.
Shapiro,
L.
Gandhi
(2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Clinical Cancer Research, 18
-
J.
Becker,
A.
Stang,
J.
Decaprio,
L.
Cerroni,
C.
Lebbé,
M.
Veness,
P.
Nghiem
(2017)
Merkel cell carcinoma
Nature Reviews Disease Primers, 3
-
(
SchadendorfDLebbéCzur HausenA, et al
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Euro J Cancer
2017; 71: 53–69.)
SchadendorfDLebbéCzur HausenA, et al
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Euro J Cancer
2017; 71: 53–69.
SchadendorfDLebbéCzur HausenA, et al
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Euro J Cancer
2017; 71: 53–69.,
SchadendorfDLebbéCzur HausenA, et al
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Euro J Cancer
2017; 71: 53–69.
-
(
VerhaegenMEMangelbergerDWeickJW, et al
Merkel cell carcinoma dependence on Bcl-2 family members for survival. J Invest Dermatol
2014; 134: 2241–2250.24614157)
VerhaegenMEMangelbergerDWeickJW, et al
Merkel cell carcinoma dependence on Bcl-2 family members for survival. J Invest Dermatol
2014; 134: 2241–2250.24614157
VerhaegenMEMangelbergerDWeickJW, et al
Merkel cell carcinoma dependence on Bcl-2 family members for survival. J Invest Dermatol
2014; 134: 2241–2250.24614157,
VerhaegenMEMangelbergerDWeickJW, et al
Merkel cell carcinoma dependence on Bcl-2 family members for survival. J Invest Dermatol
2014; 134: 2241–2250.24614157
-
M.
Verhaegen,
Doris
Mangelberger,
Jack
Weick,
Tracy
Vozheiko,
P.
Harms,
K.
Nash,
E.
Quintana,
Paul
Baciu,
T.
Johnson,
C.
Bichakjian,
A.
Dlugosz
(2014)
Merkel Cell Carcinoma Dependence on Bcl-2 Family Members for Survival
The Journal of investigative dermatology, 134
-
(
RobertsAWSeymourJFBrownJR, et al
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol
2012; 30: 488–496.22184378)
RobertsAWSeymourJFBrownJR, et al
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol
2012; 30: 488–496.22184378
RobertsAWSeymourJFBrownJR, et al
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol
2012; 30: 488–496.22184378,
RobertsAWSeymourJFBrownJR, et al
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol
2012; 30: 488–496.22184378
-
I.
Vermes,
C.
Haanen,
H.
Steffens-Nakken,
Chris
Reutellingsperger
(1995)
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.
Journal of immunological methods, 184 1
-
O.
Gul,
H.
Basaga,
O.
Kutuk
(2008)
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures.
Briefings in functional genomics & proteomics, 7 1
-
A.
Roberts,
R.
Advani,
B.
Kahl,
D.
Persky,
J.
Sweetenham,
D.
Carney,
Jianning
Yang,
Todd
Busman,
S.
Enschede,
R.
Humerickhouse,
J.
Seymour
(2015)
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
British Journal of Haematology, 170
-
(
KippsTJEradatHGrosickiS, et al
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma
2015; 56: 2826–2833.25797560)
KippsTJEradatHGrosickiS, et al
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma
2015; 56: 2826–2833.25797560
KippsTJEradatHGrosickiS, et al
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma
2015; 56: 2826–2833.25797560,
KippsTJEradatHGrosickiS, et al
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma
2015; 56: 2826–2833.25797560
-
L.
Gandhi,
D.
Camidge,
Moacyr
Oliveira,
P.
Bonomi,
D.
Gandara,
D.
Khaira,
C.
Hann,
E.
Mckeegan,
E.
Litvinovich,
P.
Hemken,
C.
Dive,
S.
Enschede,
C.
Nolan,
Y.
Chiu,
T.
Busman,
H.
Xiong,
A.
Krivoshik,
R.
Humerickhouse,
G.
Shapiro,
C.
Rudin
(2011)
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 7
-
Y.
Ge,
A.
Dombkowski,
K.
Lafiura,
D.
Tatman,
R.
Yedidi,
M.
Stout,
S.
Buck,
G.
Massey,
D.
Becton,
H.
Weinstein,
Y.
Ravindranath,
L.
Matherly,
J.
Taub
(2006)
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Blood, 107 4
-
C.
Hafner,
R.
Houben,
Anne
Baeurle,
Cathrin
Ritter,
D.
Schrama,
M.
Landthaler,
J.
Becker
(2012)
Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma
PLoS ONE, 7
-
(
IyerJGBlomADoumaniR, et al
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med
2016; 5: 2294–2301.27431483)
IyerJGBlomADoumaniR, et al
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med
2016; 5: 2294–2301.27431483
IyerJGBlomADoumaniR, et al
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med
2016; 5: 2294–2301.27431483,
IyerJGBlomADoumaniR, et al
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med
2016; 5: 2294–2301.27431483
-
(
HafnerCHoubenRBaeurleA, et al
Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One
2012; 7: e31255.22363598)
HafnerCHoubenRBaeurleA, et al
Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One
2012; 7: e31255.22363598
HafnerCHoubenRBaeurleA, et al
Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One
2012; 7: e31255.22363598,
HafnerCHoubenRBaeurleA, et al
Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One
2012; 7: e31255.22363598
-
(
García-ArandaMPérez-RuizERedondoM.
Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci
2018; 19.)
García-ArandaMPérez-RuizERedondoM.
Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci
2018; 19.
García-ArandaMPérez-RuizERedondoM.
Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci
2018; 19.,
García-ArandaMPérez-RuizERedondoM.
Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci
2018; 19.
-
(
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.)
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.,
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
-
E.
Senkevitch,
S.
Durum
(2017)
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
Cytokine, 98
-
V.
Marmol,
C.
Lebbé
(2019)
New perspectives in Merkel cell carcinoma
Current Opinion in Oncology, 31
-
(
RobertsAWAdvaniRHKahlBS, et al
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol
2015; 170: 669–678.25942994)
RobertsAWAdvaniRHKahlBS, et al
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol
2015; 170: 669–678.25942994
RobertsAWAdvaniRHKahlBS, et al
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol
2015; 170: 669–678.25942994,
RobertsAWAdvaniRHKahlBS, et al
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol
2015; 170: 669–678.25942994
-
(
NardiVSongYSantamaria-BarriaJA, et al
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res
2012; 18: 1227–1236.22261808)
NardiVSongYSantamaria-BarriaJA, et al
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res
2012; 18: 1227–1236.22261808
NardiVSongYSantamaria-BarriaJA, et al
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res
2012; 18: 1227–1236.22261808,
NardiVSongYSantamaria-BarriaJA, et al
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res
2012; 18: 1227–1236.22261808
-
Micahael
Tomz,
J.
Wittenberg,
Gary
King
(2003)
Clarify: Software for Interpreting and Presenting Statistical Results
Journal of Statistical Software, 8
-
Jocelyn
Joseph,
Chrystia
Zobniw,
Jennifer
Davis,
Jaime
Anderson,
V.
Trinh
(2018)
Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma
Annals of Pharmacotherapy, 52
-
(
SenkevitchEDurumS.
The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine
2017; 98: 33–41.28277287)
SenkevitchEDurumS.
The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine
2017; 98: 33–41.28277287
SenkevitchEDurumS.
The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine
2017; 98: 33–41.28277287,
SenkevitchEDurumS.
The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine
2017; 98: 33–41.28277287
-
M.
García-Aranda,
E.
Pérez-Ruiz,
M.
Redondo
(2018)
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
International Journal of Molecular Sciences, 19
-
E.
Chteinberg,
D.
Rennspiess,
Ryan
Sambo,
S.
Tauchmann,
N.
Kelleners-Smeets,
V.
Winnepenninckx,
E.
Speel,
A.
Kurz,
M.
Zenke,
A.
Hausen
(2018)
Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma
Oncotarget, 9
-
(
Del MarmolVLebbéC
New perspectives in Merkel cell carcinoma. Curr Opin Oncol
2019; 31: 72–83.30694842)
Del MarmolVLebbéC
New perspectives in Merkel cell carcinoma. Curr Opin Oncol
2019; 31: 72–83.30694842
Del MarmolVLebbéC
New perspectives in Merkel cell carcinoma. Curr Opin Oncol
2019; 31: 72–83.30694842,
Del MarmolVLebbéC
New perspectives in Merkel cell carcinoma. Curr Opin Oncol
2019; 31: 72–83.30694842
-
Erinna
Lee,
Tiffany
Harris,
Sharon
Tran,
M.
Evangelista,
S.
Arulananda,
T.
John,
Celeste
Ramnac,
Chloe
Hobbs,
Haoran
Zhu,
Haoran
Zhu,
G.
Gunasingh,
D.
Segal,
A.
Behren,
J.
Cebon,
A.
Dobrovic,
J.
Mariadason,
A.
Strasser,
A.
Strasser,
Leona
Rohrbeck,
Leona
Rohrbeck,
N.
Haass,
M.
Herold,
M.
Herold,
W.
Fairlie
(2019)
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Cell Death & Disease, 10
-
E.
Lipson,
Jeremy
Vincent,
M.
Loyo,
L.
Kagohara,
Brandon
Luber,
Hao
Wang,
Haiying
Xu,
S.
Nayar,
Timothy
Wang,
D.
Sidransky,
R.
Anders,
S.
Topalian,
J.
Taube
(2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Cancer Immunology Research, 1
-
R.
Team
(2014)
R: A language and environment for statistical computing.
MSOR connections, 1
-
A.
Azmahani,
Yasuhiro
Nakamura,
H.
Ishida,
K.
McNamara,
T.
Fujimura,
T.
Haga,
A.
Hashimoto,
S.
Aiba,
H.
Sasano
(2016)
Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis.
Human pathology, 56
-
F.
Pareja,
David
Macleod,
C.
Shu,
J.
Crary,
P.
Canoll,
A.
Ross,
M.
Siegelin
(2014)
PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD
Molecular Cancer Research, 12
-
(
KaeferAYangJNoertersheuserP, et al
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol
2014; 74: 593–602.25053389)
KaeferAYangJNoertersheuserP, et al
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol
2014; 74: 593–602.25053389
KaeferAYangJNoertersheuserP, et al
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol
2014; 74: 593–602.25053389,
KaeferAYangJNoertersheuserP, et al
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol
2014; 74: 593–602.25053389
-
A.
Hausen,
D.
Rennspiess,
V.
Winnepenninckx,
E.
Speel,
A.
Kurz
(2013)
Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry.
Cancer research, 73 16
-
(
RahmaniMAustMMAttkissonE, et al
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res
2013; 73: 1340–1351.23243017)
RahmaniMAustMMAttkissonE, et al
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res
2013; 73: 1340–1351.23243017
RahmaniMAustMMAttkissonE, et al
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res
2013; 73: 1340–1351.23243017,
RahmaniMAustMMAttkissonE, et al
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res
2013; 73: 1340–1351.23243017
-
(
VermesIHaanenCSteffens-NakkenH, et al
A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods
1995; 184: 39–51.7622868)
VermesIHaanenCSteffens-NakkenH, et al
A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods
1995; 184: 39–51.7622868
VermesIHaanenCSteffens-NakkenH, et al
A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods
1995; 184: 39–51.7622868,
VermesIHaanenCSteffens-NakkenH, et al
A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods
1995; 184: 39–51.7622868
-
(
SurMAlArdatiHRossC, et al
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol
2007; 20: 1113–1120.17885674)
SurMAlArdatiHRossC, et al
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol
2007; 20: 1113–1120.17885674
SurMAlArdatiHRossC, et al
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol
2007; 20: 1113–1120.17885674,
SurMAlArdatiHRossC, et al
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol
2007; 20: 1113–1120.17885674
-
(2019)
Expression and prognostic significance of programmed deathligand 1 (PD-L1) in Merkel cell carcinoma
-
(
LyngaaRPedersenNWSchramaD, et al
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res
2014; 20: 1768–1778.24526738)
LyngaaRPedersenNWSchramaD, et al
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res
2014; 20: 1768–1778.24526738
LyngaaRPedersenNWSchramaD, et al
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res
2014; 20: 1768–1778.24526738,
LyngaaRPedersenNWSchramaD, et al
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res
2014; 20: 1768–1778.24526738
-
(
Ligges and MächlerM
Scatterplot3d - an R package for visualizing multivariate data. Journal of Statistical Software
2003; 8: 1–20.)
Ligges and MächlerM
Scatterplot3d - an R package for visualizing multivariate data. Journal of Statistical Software
2003; 8: 1–20.
Ligges and MächlerM
Scatterplot3d - an R package for visualizing multivariate data. Journal of Statistical Software
2003; 8: 1–20.,
Ligges and MächlerM
Scatterplot3d - an R package for visualizing multivariate data. Journal of Statistical Software
2003; 8: 1–20.
-
P.
Harms,
Pankaj
Vats,
M.
Verhaegen,
D.
Robinson,
Yi-Mi
Wu,
S.
Dhanasekaran,
N.
Palanisamy,
J.
Siddiqui,
Xuhong
Cao,
Fengyun
Su,
Rui
Wang,
Hong
Xiao,
L.
Kunju,
R.
Mehra,
S.
Tomlins,
D.
Fullen,
C.
Bichakjian,
T.
Johnson,
A.
Dlugosz,
A.
Chinnaiyan
(2015)
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.
Cancer research, 75 18
-
J.
Iyer,
A.
Blom,
Ryan
Doumani,
C.
Lewis,
E.
Tarabadkar,
A.
Anderson,
Christine
Ma,
Amy
Bestick,
U.
Parvathaneni,
S.
Bhatia,
P.
Nghiem
(2016)
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Cancer Medicine, 5
-
(
GeYDombkowskiAALaFiuraKM, et al
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood
2006; 107: 1570–1581.16249385)
GeYDombkowskiAALaFiuraKM, et al
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood
2006; 107: 1570–1581.16249385
GeYDombkowskiAALaFiuraKM, et al
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood
2006; 107: 1570–1581.16249385,
GeYDombkowskiAALaFiuraKM, et al
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood
2006; 107: 1570–1581.16249385
-
(
LaiJHFlemingKELyTY, et al
Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors. Hum Pathol
2015; 46: 1290–1296.26099430)
LaiJHFlemingKELyTY, et al
Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors. Hum Pathol
2015; 46: 1290–1296.26099430
LaiJHFlemingKELyTY, et al
Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors. Hum Pathol
2015; 46: 1290–1296.26099430,
LaiJHFlemingKELyTY, et al
Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors. Hum Pathol
2015; 46: 1290–1296.26099430
-
M.
Rahmani,
J.
Nkwocha,
Elisa
Hawkins,
X.
Pei,
Rebecca
Parker,
M.
Kmieciak,
J.
Leverson,
D.
Sampath,
A.
Ferreira-Gonzalez,
S.
Grant
(2018)
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Cancer research, 78 11
-
D.
Potter,
M.
Galvin,
Stewart
Brown,
A.
Lallo,
C.
Hodgkinson,
F.
Blackhall,
C.
Morrow,
C.
Dive
(2016)
Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Molecular Cancer Therapeutics, 15
-
M.
Samimi,
T.
Kervarrec,
A.
Touzé
(2020)
Immunobiology of Merkel cell carcinoma.
Current Opinion in Oncology
-
H.
Sahi,
V.
Koljonen,
Heli
Kavola,
C.
Haglund,
E.
Tukiainen,
H.
Sihto,
T.
Böhling
(2012)
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus
Virchows Archiv, 461
-
(2018)
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CAaltered solid tumors: results from the first-inhuman study
-
(2013)
PDL1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival
-
(
VillaniAFabbrociniGCostaC, et al
Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther
2019; 9: 209–222.)
VillaniAFabbrociniGCostaC, et al
Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther
2019; 9: 209–222.
VillaniAFabbrociniGCostaC, et al
Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther
2019; 9: 209–222.,
VillaniAFabbrociniGCostaC, et al
Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther
2019; 9: 209–222.
-
(
SahiHKoljonenVKavolaH, et al
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch
2012; 461: 553–559.22976527)
SahiHKoljonenVKavolaH, et al
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch
2012; 461: 553–559.22976527
SahiHKoljonenVKavolaH, et al
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch
2012; 461: 553–559.22976527,
SahiHKoljonenVKavolaH, et al
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch
2012; 461: 553–559.22976527
-
C.
Knapp,
Zena
Sayegh,
M.
Schell,
B.
Rawal,
T.
Ochoa,
V.
Sondak,
J.
Messina
(2012)
Expression of CXCR4, E-Cadherin, Bcl-2, and Survivin in Merkel Cell Carcinoma: An Immunohistochemical Study Using a Tissue Microarray
The American Journal of Dermatopathology, 34
-
(
ChouTC.
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res
2010; 70: 440–446.20068163)
ChouTC.
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res
2010; 70: 440–446.20068163
ChouTC.
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res
2010; 70: 440–446.20068163,
ChouTC.
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res
2010; 70: 440–446.20068163
-
U.
Ligges,
M.
Maechler
(2003)
Scatterplot3d - an R package for visualizing multivariate data
Journal of Statistical Software, 008
-
P.
Harms,
K.
Harms,
P.
Moore,
J.
Decaprio,
P.
Nghiem,
M.
Wong,
I.
Brownell
(2018)
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Nature Reviews. Clinical Oncology, 15
-
(
SamimiMKervarrecTTouzeA.
Immunobiology of Merkel cell carcinoma. Curr Opin Oncol
2020; 32: 114–121.31972727)
SamimiMKervarrecTTouzeA.
Immunobiology of Merkel cell carcinoma. Curr Opin Oncol
2020; 32: 114–121.31972727
SamimiMKervarrecTTouzeA.
Immunobiology of Merkel cell carcinoma. Curr Opin Oncol
2020; 32: 114–121.31972727,
SamimiMKervarrecTTouzeA.
Immunobiology of Merkel cell carcinoma. Curr Opin Oncol
2020; 32: 114–121.31972727
-
T.
Kipps,
H.
Eradat,
S.
Grosicki,
J.
Catalano,
W.
Cosolo,
I.
Dyagil,
Sreeni
Yalamanchili,
A.
Chai,
S.
Sahasranaman,
E.
Punnoose,
D.
Hurst,
H.
Pylypenko
(2015)
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Leukemia & Lymphoma, 56
-
(
KennedyMMBlessingKKingG, et al
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol
1996; 18: 273–277.8806961)
KennedyMMBlessingKKingG, et al
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol
1996; 18: 273–277.8806961
KennedyMMBlessingKKingG, et al
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol
1996; 18: 273–277.8806961,
KennedyMMBlessingKKingG, et al
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol
1996; 18: 273–277.8806961
-
R.
Lyngaa,
N.
Pedersen,
D.
Schrama,
C.
Thrue,
D.
Ibrani,
Ö.
Met,
P.
Straten,
P.
Nghiem,
J.
Becker,
S.
Hadrup
(2014)
T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Clinical Cancer Research, 20
-
(
JosephJZobniwCDavisJ, et al
Avelumab: a review of its application in metastatic Merkel cell carcinoma. Ann Pharmacother
2018; 52: 928–935.29616562)
JosephJZobniwCDavisJ, et al
Avelumab: a review of its application in metastatic Merkel cell carcinoma. Ann Pharmacother
2018; 52: 928–935.29616562
JosephJZobniwCDavisJ, et al
Avelumab: a review of its application in metastatic Merkel cell carcinoma. Ann Pharmacother
2018; 52: 928–935.29616562,
JosephJZobniwCDavisJ, et al
Avelumab: a review of its application in metastatic Merkel cell carcinoma. Ann Pharmacother
2018; 52: 928–935.29616562
-
(
MarkhamA.
Alpelisib: first global approval. Drugs
2019; 79: 1249–1253.31256368)
MarkhamA.
Alpelisib: first global approval. Drugs
2019; 79: 1249–1253.31256368
MarkhamA.
Alpelisib: first global approval. Drugs
2019; 79: 1249–1253.31256368,
MarkhamA.
Alpelisib: first global approval. Drugs
2019; 79: 1249–1253.31256368
-
(
Zur HausenARennspiessDWinnepenninckxV, et al
Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. Cancer Res
2013; 73: 4982–4987.23576560)
Zur HausenARennspiessDWinnepenninckxV, et al
Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. Cancer Res
2013; 73: 4982–4987.23576560
Zur HausenARennspiessDWinnepenninckxV, et al
Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. Cancer Res
2013; 73: 4982–4987.23576560,
Zur HausenARennspiessDWinnepenninckxV, et al
Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. Cancer Res
2013; 73: 4982–4987.23576560
-
(
GulOBasagaHKutukO.
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic
2008; 7: 27–34.18283052)
GulOBasagaHKutukO.
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic
2008; 7: 27–34.18283052
GulOBasagaHKutukO.
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic
2008; 7: 27–34.18283052,
GulOBasagaHKutukO.
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic
2008; 7: 27–34.18283052
-
F.
André,
E.
Ciruelos,
G.
Rubovszky,
M.
Campone,
S.
Loibl,
H.
Rugo,
H.
Iwata,
P.
Conte,
I.
Mayer,
B.
Kaufman,
T.
Yamashita,
Yung-Feng
Lu,
K.
Inoue,
M.
Takahashi,
Z.
Pápai,
A.
Longin,
D.
Mills,
C.
Wilke,
S.
Hirawat,
D.
Juric
(2018)
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
M.
Sur,
Hosam
Alardati,
Catherine
Ross,
S.
Alowami
(2007)
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis
Modern Pathology, 20
-
(
AzmahaniANakamuraYIshidaH, et al
Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. Hum Pathol
2016; 56: 128–133.27343835)
AzmahaniANakamuraYIshidaH, et al
Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. Hum Pathol
2016; 56: 128–133.27343835
AzmahaniANakamuraYIshidaH, et al
Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. Hum Pathol
2016; 56: 128–133.27343835,
AzmahaniANakamuraYIshidaH, et al
Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. Hum Pathol
2016; 56: 128–133.27343835
-
(
RahmaniMNkwochaJHawkinsE, et al
Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res
2018; 78: 3075–3086.29559471)
RahmaniMNkwochaJHawkinsE, et al
Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res
2018; 78: 3075–3086.29559471
RahmaniMNkwochaJHawkinsE, et al
Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res
2018; 78: 3075–3086.29559471,
RahmaniMNkwochaJHawkinsE, et al
Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res
2018; 78: 3075–3086.29559471
-
M.
Rahmani,
M.
Aust,
Elisa
Attkisson,
David
Williams,
A.
Ferreira-Gonzalez,
S.
Grant
(2013)
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer research, 73 4
-
(
RudinCMHannCLGaronEB, et al
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res
2012; 18: 3163–3169.22496272)
RudinCMHannCLGaronEB, et al
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res
2012; 18: 3163–3169.22496272
RudinCMHannCLGaronEB, et al
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res
2012; 18: 3163–3169.22496272,
RudinCMHannCLGaronEB, et al
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res
2012; 18: 3163–3169.22496272
-
(
ChteinbergERennspiessDSamboR, et al
Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma. Oncotarget
2018; 9.)
ChteinbergERennspiessDSamboR, et al
Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma. Oncotarget
2018; 9.
ChteinbergERennspiessDSamboR, et al
Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma. Oncotarget
2018; 9.,
ChteinbergERennspiessDSamboR, et al
Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma. Oncotarget
2018; 9.
-
O.
Afanasiev,
Lola
Yelistratova,
Natalie
Miller,
Kotaro
Nagase,
K.
Paulson,
J.
Iyer,
D.
Ibrani,
D.
Koelle,
P.
Nghiem
(2013)
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Clinical Cancer Research, 19
-
(
JuricDRodonJTaberneroJ, et al
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol
2018; 36: 1291–1299.29401002)
JuricDRodonJTaberneroJ, et al
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol
2018; 36: 1291–1299.29401002
JuricDRodonJTaberneroJ, et al
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol
2018; 36: 1291–1299.29401002,
JuricDRodonJTaberneroJ, et al
Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol
2018; 36: 1291–1299.29401002
-
(
GandhiLCamidgeDROliveiraMRd, et al
Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol
2011; 29: 909–916.21282543)
GandhiLCamidgeDROliveiraMRd, et al
Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol
2011; 29: 909–916.21282543
GandhiLCamidgeDROliveiraMRd, et al
Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol
2011; 29: 909–916.21282543,
GandhiLCamidgeDROliveiraMRd, et al
Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol
2011; 29: 909–916.21282543
-
Jonathan
Lai,
K.
Fleming,
T.
Ly,
S.
Pasternak,
M.
Godlewski,
S.
Doucette,
N.
Walsh
(2015)
Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors.
Human pathology, 46 9
-
A.
Plettenberg,
J.
Pammer,
E.
Tschachler
(1996)
Merkel cells and Merkel cell carcinoma express the BCL‐2 proto‐oncogene
Experimental Dermatology, 5
-
(
RichterIDvorakT.
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma. J Buon
2019; 24: 2155–2160.31786889)
RichterIDvorakT.
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma. J Buon
2019; 24: 2155–2160.31786889
RichterIDvorakT.
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma. J Buon
2019; 24: 2155–2160.31786889,
RichterIDvorakT.
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma. J Buon
2019; 24: 2155–2160.31786889
-
C.
Schneider,
W.
Rasband,
K.
Eliceiri
(2012)
NIH Image to ImageJ: 25 years of image analysis
Nature Methods, 9
-
(
KnappCFSayeghZSchellMJ, et al
Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol
2012; 34: 592–596.22814318)
KnappCFSayeghZSchellMJ, et al
Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol
2012; 34: 592–596.22814318
KnappCFSayeghZSchellMJ, et al
Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol
2012; 34: 592–596.22814318,
KnappCFSayeghZSchellMJ, et al
Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol
2012; 34: 592–596.22814318
-
A.
Käfer,
Jianning
Yang,
P.
Noertersheuser,
S.
Mensing,
R.
Humerickhouse,
W.
Awni,
H.
Xiong
(2014)
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
Cancer Chemotherapy and Pharmacology, 74
-
V.
Nardi,
Youngchul
Song,
Juan
Santamaria-Barria,
A.
Cosper,
Quynh
Lam,
A.
Faber,
G.
Boland,
B.
Yeap,
K.
Bergethon,
V.
Scialabba,
H.
Tsao,
J.
Settleman,
D.
Ryan,
D.
Borger,
A.
Bhan,
M.
Hoang,
A.
Iafrate,
J.
Cusack,
J.
Engelman,
D.
Dias-Santagata
(2012)
Activation of PI3K Signaling in Merkel Cell Carcinoma
Clinical Cancer Research, 18
-
A.
Roberts,
J.
Seymour,
Jennifer
Brown,
W.
Wierda,
T.
Kipps,
S.
Khaw,
D.
Carney,
Simon
He,
D.
Huang,
H.
Xiong,
Yue
Cui,
T.
Busman,
E.
Mckeegan,
A.
Krivoshik,
S.
Enschede,
R.
Humerickhouse
(2012)
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 5
-
(
LipsonEJVincentJGLoyoM, et al
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res
2013; 1: 54–63.24416729)
LipsonEJVincentJGLoyoM, et al
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res
2013; 1: 54–63.24416729
LipsonEJVincentJGLoyoM, et al
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res
2013; 1: 54–63.24416729,
LipsonEJVincentJGLoyoM, et al
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res
2013; 1: 54–63.24416729
-
(
AndréFCiruelosEMRubovszkyG, et al
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol
2018; 29: viii709.)
AndréFCiruelosEMRubovszkyG, et al
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol
2018; 29: viii709.
AndréFCiruelosEMRubovszkyG, et al
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol
2018; 29: viii709.,
AndréFCiruelosEMRubovszkyG, et al
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol
2018; 29: viii709.
-
(
WilsonWHO’ConnorOACzuczmanMS, et al
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol
2010; 11: 1149–1159.21094089)
WilsonWHO’ConnorOACzuczmanMS, et al
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol
2010; 11: 1149–1159.21094089
WilsonWHO’ConnorOACzuczmanMS, et al
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol
2010; 11: 1149–1159.21094089,
WilsonWHO’ConnorOACzuczmanMS, et al
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol
2010; 11: 1149–1159.21094089
-
(
LeeEFHarrisTJTranS, et al
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis
2019; 10: 342.31019203)
LeeEFHarrisTJTranS, et al
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis
2019; 10: 342.31019203
LeeEFHarrisTJTranS, et al
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis
2019; 10: 342.31019203,
LeeEFHarrisTJTranS, et al
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis
2019; 10: 342.31019203
-
A.
Markham
(2019)
Alpelisib: First Global Approval
Drugs, 79
-
(
BadarniMPrasadMBalabanN, et al
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight
2019; 4.)
BadarniMPrasadMBalabanN, et al
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight
2019; 4.
BadarniMPrasadMBalabanN, et al
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight
2019; 4.,
BadarniMPrasadMBalabanN, et al
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight
2019; 4.
-
(
ParejaFMacleodDShuC, et al
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res
2014; 12: 987–1001.24757258)
ParejaFMacleodDShuC, et al
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res
2014; 12: 987–1001.24757258
ParejaFMacleodDShuC, et al
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res
2014; 12: 987–1001.24757258,
ParejaFMacleodDShuC, et al
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res
2014; 12: 987–1001.24757258
-
(
SchneiderCARasbandWSEliceiriKW.
NIH Image to ImageJ: 25 years of image analysis. Nat Methods
2012; 9: 671–675.22930834)
SchneiderCARasbandWSEliceiriKW.
NIH Image to ImageJ: 25 years of image analysis. Nat Methods
2012; 9: 671–675.22930834
SchneiderCARasbandWSEliceiriKW.
NIH Image to ImageJ: 25 years of image analysis. Nat Methods
2012; 9: 671–675.22930834,
SchneiderCARasbandWSEliceiriKW.
NIH Image to ImageJ: 25 years of image analysis. Nat Methods
2012; 9: 671–675.22930834
-
(
AfanasievOKYelistratovaLMillerN, et al
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res
2013; 19: 5351–5360.23922299)
AfanasievOKYelistratovaLMillerN, et al
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res
2013; 19: 5351–5360.23922299
AfanasievOKYelistratovaLMillerN, et al
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res
2013; 19: 5351–5360.23922299,
AfanasievOKYelistratovaLMillerN, et al
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res
2013; 19: 5351–5360.23922299
-
(
PlettenbergAPammerJTschachlerE.
Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol
1996; 5: 102–107.8734919)
PlettenbergAPammerJTschachlerE.
Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol
1996; 5: 102–107.8734919
PlettenbergAPammerJTschachlerE.
Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol
1996; 5: 102–107.8734919,
PlettenbergAPammerJTschachlerE.
Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol
1996; 5: 102–107.8734919
-
A.
Villani,
G.
Fabbrocini,
C.
Costa,
Maria
Annunziata,
M.
Scalvenzi
(2019)
Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies
Dermatology and Therapy, 9
-
T.
Chou
(2010)
Drug combination studies and their synergy quantification using the Chou-Talalay method.
Cancer research, 70 2
-
D.
Schadendorf,
C.
Lebbé,
A.
Hausen,
M.
Avril,
S.
Hariharan,
M.
Bharmal,
J.
Becker
(2017)
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs.
European journal of cancer, 71
-
(
BeckerJCLorenzEUgurelS, et al
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget
2017; 8: 79731–79741.29108353)
BeckerJCLorenzEUgurelS, et al
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget
2017; 8: 79731–79741.29108353
BeckerJCLorenzEUgurelS, et al
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget
2017; 8: 79731–79741.29108353,
BeckerJCLorenzEUgurelS, et al
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget
2017; 8: 79731–79741.29108353
-
(
StratikopoulosEEKiessNSzabolcsM, et al
Mouse ER+/PIK3CA(H1047R) breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene
2019; 38: 47–59.30076411)
StratikopoulosEEKiessNSzabolcsM, et al
Mouse ER+/PIK3CA(H1047R) breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene
2019; 38: 47–59.30076411
StratikopoulosEEKiessNSzabolcsM, et al
Mouse ER+/PIK3CA(H1047R) breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene
2019; 38: 47–59.30076411,
StratikopoulosEEKiessNSzabolcsM, et al
Mouse ER+/PIK3CA(H1047R) breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene
2019; 38: 47–59.30076411
-
(
BeckerJCStangADeCaprioJA, et al
Merkel cell carcinoma. Nat Rev Dis Primers
2017; 3: 17077.29072302)
BeckerJCStangADeCaprioJA, et al
Merkel cell carcinoma. Nat Rev Dis Primers
2017; 3: 17077.29072302
BeckerJCStangADeCaprioJA, et al
Merkel cell carcinoma. Nat Rev Dis Primers
2017; 3: 17077.29072302,
BeckerJCStangADeCaprioJA, et al
Merkel cell carcinoma. Nat Rev Dis Primers
2017; 3: 17077.29072302
-
D.
Juric,
J.
Rodón,
J.
Tabernero,
F.
Janku,
H.
Burris,
J.
Schellens,
M.
Middleton,
J.
Berlin,
M.
Schuler,
M.
Gil-Martin,
H.
Rugo,
R.
Seggewiss-Bernhardt,
A.
Huang,
D.
Bootle,
D.
Demanse,
L.
Blumenstein,
C.
Coughlin,
C.
Quadt,
J.
Baselga
(2018)
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 13
-
(
FeinmesserMHalpernMFenigE, et al
Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?
Hum Pathol
1999; 30: 1367–1372.10571519)
FeinmesserMHalpernMFenigE, et al
Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?
Hum Pathol
1999; 30: 1367–1372.10571519
FeinmesserMHalpernMFenigE, et al
Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?
Hum Pathol
1999; 30: 1367–1372.10571519,
FeinmesserMHalpernMFenigE, et al
Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?
Hum Pathol
1999; 30: 1367–1372.10571519
-
M.
Feinmesser,
M.
Halpern,
E.
Fenig,
C.
Tsabari,
E.
Hodak,
J.
Sulkes,
B.
Brenner,
E.
Okon
(1999)
Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?
Human pathology, 30 11
-
E.
Stratikopoulos,
Nicole
Kiess,
M.
Szabolcs,
Sarah
Pegno,
Cheung
Kakit,
Xuewei
Wu,
Poulikos
Poulikakos,
Pamela
Cheung,
H.
Schmidt,
R.
Parsons
(2018)
Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents
Oncogene, 38
-
W.
Wilson,
O.
O’Connor,
M.
Czuczman,
A.
LaCasce,
J.
Gerecitano,
J.
Leonard,
A.
Tulpule,
K.
Dunleavy,
H.
Xiong,
Y.
Chiu,
Yue
Cui,
T.
Busman,
S.
Elmore,
S.
Rosenberg,
A.
Krivoshik,
S.
Enschede,
R.
Humerickhouse
(2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
The Lancet. Oncology, 11 12
-
M.
Kennedy,
K.
Blessing,
G.
King,
K.
Kerr
(1996)
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study.
The American Journal of dermatopathology, 18 3
-
J.
Becker,
E.
Lorenz,
S.
Ugurel,
T.
Eigentler,
F.
Kiecker,
C.
Pföhler,
I.
Kellner,
F.
Meier,
K.
Kähler,
P.
Mohr,
C.
Berking,
G.
Haas,
C.
Helwig,
D.
Oksen,
D.
Schadendorf,
L.
Mahnke,
M.
Bharmal
(2017)
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
Oncotarget, 8
-
(
HarmsPWHarmsKLMoorePS, et al
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol
2018; 15: 763–776.30287935)
HarmsPWHarmsKLMoorePS, et al
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol
2018; 15: 763–776.30287935
HarmsPWHarmsKLMoorePS, et al
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol
2018; 15: 763–776.30287935,
HarmsPWHarmsKLMoorePS, et al
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol
2018; 15: 763–776.30287935